Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 239 participants.
Also called NCT04456803
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 239 participants
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
- Registry
-
NCT04456803
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04456803. Randomized; no masking; primary purpose treatment. Start 2019-05-24 (actual); primary completion 2022-09-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Condition
- Hyperphosphatemia
- Condition
- End Stage Renal Disease
- Condition
- ESRD
- Intervention (Drug)
- Ferric citrate tablet
- Intervention (Drug)
- Sevelamer carbonate tablet
- Lead sponsor
- Sinomune Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct04456803- Content hash
e830bdb708fc74d7deaf38669827d87eb432f3bd1ec7d6ca025dd5e00e5ca327